Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy.

Non-ST-segment elevation myocardial infarction coronary angiography heart failure prognosis

Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
20 Oct 2020
Historique:
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 10 2020
Statut: aheadofprint

Résumé

Previous studies published before the era of systematic early invasive strategy have reported a higher mortality in non-ST-segment elevation myocardial infarction patients with heart failure. The aim of our study was to compare the clinical characteristics, outcomes and causes of death of patients according to their heart failure status at admission in a large non-ST-segment elevation myocardial infarction population with planned early invasive management. We performed a post-hoc analysis of the Treatment of Acute Coronary Syndrome with Otamixaban randomised trial which included non-ST-segment elevation myocardial infarction patients with systematic coronary angiography within 72 h. Patients were categorised according to presence or absence of heart failure (Killip grade ≥2) at admission. A total of 13,172 patients were enrolled, of whom 944 (7.2%) had heart failure. At day 30, death occurred in 213 patients (1.6%) and cardiovascular death was the dominant cause of death in both groups ((with vs without heart failure) 78.8% vs 78.4%, Non-ST-segment elevation myocardial infarction patients with heart failure at admission still have worse outcomes than those without heart failure, even with systematic early invasive strategy. Further efforts are needed to improve the prognosis of these high risk patients.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies published before the era of systematic early invasive strategy have reported a higher mortality in non-ST-segment elevation myocardial infarction patients with heart failure. The aim of our study was to compare the clinical characteristics, outcomes and causes of death of patients according to their heart failure status at admission in a large non-ST-segment elevation myocardial infarction population with planned early invasive management.
METHODS METHODS
We performed a post-hoc analysis of the Treatment of Acute Coronary Syndrome with Otamixaban randomised trial which included non-ST-segment elevation myocardial infarction patients with systematic coronary angiography within 72 h. Patients were categorised according to presence or absence of heart failure (Killip grade ≥2) at admission.
RESULTS RESULTS
A total of 13,172 patients were enrolled, of whom 944 (7.2%) had heart failure. At day 30, death occurred in 213 patients (1.6%) and cardiovascular death was the dominant cause of death in both groups ((with vs without heart failure) 78.8% vs 78.4%,
CONCLUSION CONCLUSIONS
Non-ST-segment elevation myocardial infarction patients with heart failure at admission still have worse outcomes than those without heart failure, even with systematic early invasive strategy. Further efforts are needed to improve the prognosis of these high risk patients.

Identifiants

pubmed: 33081496
doi: 10.1177/2048872619896205
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2048872619896205

Auteurs

Batric Popovic (B)

Université de Lorraine, CHRU de Nancy, Département de cardiologie, Nancy, France.

Emmanuel Sorbets (E)

Université de Paris, puis APHP, Hotel Dieu, Centre de diagnostic et de Thérapeutique; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148.

Jeremie Abtan (J)

Université de Paris, puis APHP, Hotel Dieu, Centre de diagnostic et de Thérapeutique; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148.

Marc Cohen (M)

APHP, Department of cardiology, Hôpital Bichat, France; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148; DHU FIRE, University of Paris.

Charles V Pollack (CV)

Division of Cardiology, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, Newark, New Jersey, USA.
Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, USA.

Christoph Bode (C)

Sidney Kimmel Medical College, USA.

Stephen D Wiviott (SD)

Medizinische Universitatsklinik, Freiburg, Germany.

Marc S Sabatine (MS)

Medizinische Universitatsklinik, Freiburg, Germany.

Shamir R Mehta (SR)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Witold Ruzyllo (W)

Institute of Cardiology, Warsaw, Poland.

Sunil V Rao (SV)

The Duke Clinical Research Institute, Durham, North Carolina, USA.

William J French (WJ)

David Geffen School of Medicine at UCLA, Torrance, California, USA.

Prafulla Kerkar (P)

Seth GS Medical College, India.
KEM Hospital Parel, India.

Robert G Kiss (RG)

Department of Cardiology, Military Hospital, Budapest, Hungary.

Jose Luis N Estrada (JLN)

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Yedid Elbez (Y)

Université de Paris, puis APHP, Hotel Dieu, Centre de diagnostic et de Thérapeutique; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148.

Gregory Ducrocq (G)

Université de Paris, puis APHP, Hotel Dieu, Centre de diagnostic et de Thérapeutique; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148.

Philippe Gabriel Steg (PG)

Université de Paris, puis APHP, Hotel Dieu, Centre de diagnostic et de Thérapeutique; French Alliance for Cardiovascular Trials (FACT); INSERM LVTS-U1148.
NHLI Imperial College, ICMS Royal Brompton Hospital London, United Kingdom.

Classifications MeSH